ARROWHEAD PHARMACEUTICALS, INC. (ARWR) — insider trading
Health Care · Nasdaq
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has 41 reported SEC Form 4 insider transactions in our data, including 27 open-market sales among the most recent 41 (latest 2026-06-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Cohen Matthew Gregory | Director | Grant / award / vesting | 11,882 | $0.00 | $0 | Form 4 |
| 2026-05-12 | Lu Hongbo | Director | Open-market sale | 2,970 | $76.88 | $228.3K | Form 4 |
| 2026-04-23 | Hamilton James C | Officer (Chief Medical Officer) | Open-market sale | 10,000 | $75.00 | $750.0K | Form 4 |
| 2026-04-22 | Apel Daniel Joseph | Officer (Chief Financial Officer) | Open-market sale | 8,730 | $71.92 | $627.9K | Form 4 |
| 2026-04-22 | Apel Daniel Joseph | Officer (Chief Financial Officer) | Open-market sale | 1,157 | $70.45 | $81.5K | Form 4 |
| 2026-04-22 | Apel Daniel Joseph | Officer (Chief Financial Officer) | Open-market sale | 3,208 | $70.11 | $224.9K | Form 4 |
| 2026-03-05 | Hamilton James C | Officer (Chief Medical Officer) | Open-market sale | 10,000 | $64.19 | $641.9K | Form 4 |
| 2026-01-06 | O'Brien Patrick | Officer (COO) | Grant / award / vesting | 75,000 | $0.00 | $0 | Form 4 |
| 2026-01-06 | O'Brien Patrick | Officer (COO) | Bona fide gift | 440 | $0.00 | $0 | Form 4 |
| 2026-01-06 | O'Brien Patrick | Officer (COO) | Bona fide gift | 440 | $0.00 | $0 | Form 4 |
| 2026-01-06 | O'Brien Patrick | Officer (COO) | Bona fide gift | 540 | $0.00 | $0 | Form 4 |
| 2026-01-06 | O'Brien Patrick | Officer (COO) | Bona fide gift | 540 | $0.00 | $0 | Form 4 |
| 2026-01-06 | O'Brien Patrick | Officer (COO) | Bona fide gift | 540 | $0.00 | $0 | Form 4 |
| 2026-01-06 | Apel Daniel Joseph | Officer (Chief Financial Officer) | Grant / award / vesting | 75,000 | $0.00 | $0 | Form 4 |
| 2026-01-06 | Hamilton James C | Officer (Chief Medical Officer) | Grant / award / vesting | 75,000 | $0.00 | $0 | Form 4 |
| 2026-01-05 | Hamilton James C | Officer (Chief Medical Officer) | Open-market sale | 309 | $68.00 | $21.0K | Form 4 |
| 2026-01-05 | Hamilton James C | Officer (Chief Medical Officer) | Open-market sale | 437 | $65.97 | $28.8K | Form 4 |
| 2026-01-05 | Hamilton James C | Officer (Chief Medical Officer) | Open-market sale | 1,200 | $64.49 | $77.4K | Form 4 |
| 2026-01-05 | Hamilton James C | Officer (Chief Medical Officer) | Open-market sale | 12,711 | $63.95 | $812.9K | Form 4 |
| 2026-01-05 | Hamilton James C | Officer (Chief Medical Officer) | Open-market sale | 14,792 | $63.01 | $932.0K | Form 4 |
| 2026-01-05 | Hamilton James C | Officer (Chief Medical Officer) | Open-market sale | 6,090 | $62.28 | $379.3K | Form 4 |
| 2026-01-05 | Hamilton James C | Officer (Chief Medical Officer) | Open-market sale | 4,625 | $61.24 | $283.2K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 46 | $68.00 | $3.1K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 2,336 | $64.04 | $149.6K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 5,873 | $62.91 | $369.5K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 900 | $62.25 | $56.0K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 600 | $61.12 | $36.7K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 313 | $68.00 | $21.3K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 900 | $66.01 | $59.4K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 2,700 | $64.44 | $174.0K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 11,842 | $63.84 | $756.0K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 13,451 | $62.96 | $846.9K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 6,164 | $62.23 | $383.6K | Form 4 |
| 2026-01-05 | O'Brien Patrick | Officer (COO) | Open-market sale | 4,368 | $61.20 | $267.3K | Form 4 |
| 2026-01-02 | Anzalone Christopher Richard | Director, Officer (Chief Executive Officer) | Open-market sale | 5,771 | $66.39 | $383.1K | Form 4 |
| 2026-01-02 | Anzalone Christopher Richard | Director, Officer (Chief Executive Officer) | Open-market sale | 7,416 | $65.88 | $488.6K | Form 4 |
| 2025-12-31 | O'Brien Patrick | Officer (COO) | Bona fide gift | 560 | $0.00 | $0 | Form 4 |
| 2025-12-31 | O'Brien Patrick | Officer (COO) | Bona fide gift | 560 | $0.00 | $0 | Form 4 |
| 2025-12-31 | O'Brien Patrick | Officer (COO) | Bona fide gift | 560 | $0.00 | $0 | Form 4 |
| 2025-12-31 | O'Brien Patrick | Officer (COO) | Bona fide gift | 560 | $0.00 | $0 | Form 4 |
| 2025-12-31 | O'Brien Patrick | Officer (COO) | Bona fide gift | 560 | $0.00 | $0 | Form 4 |
Ask the chat about ARWR's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
Last updated 2026-06-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.